


Next-Generation DNA-Based Delivery of Therapeutic Proteins Using MYO Technology: Preclinical Results on Incretins Receptor Agonists

Linda Sasset^{1*}, Marek M. Drozd^{1*}, Andrew D. Cameron¹, Delcora A. Campbell¹, Debnath Maji¹, Xin Yao¹, Carleigh Sussman¹, Andy T. Thompson¹, Robert Miller¹, Rachel Liberatore^{1*}


Abstract #1741

¹RenBio Inc., Long Island City, New York, USA. *corresponding authors: linda.sasset@renbio.com, marek.drozd@renbio.com or rachel.liberatore@renbio.com


MYO technology platform




1. Improves therapeutic protein expression profile *in vivo*




2. Is pDNA dose-dependent



3. Permits repeated dosing




4. Can be scaled-up to larger animal models




Versatility of MYO technology


Proof-of-concept studies demonstrate that therapeutic proteins delivered with MYO Technology are efficacious in a diverse array of disease models.




Breast Cancer




Arthritis



Influenza




Anemia




MYO technology has broad applicability and the potential to dramatically improve the accessibility and usage of therapeutic proteins

Incretin Receptor Agonists PoC studies


1. Incretin receptor agonists long-term expression after a single dose



2. Incretin receptor agonists expressed with MYO technology stimulate weight loss



3. GLP-1 expressed with MYO technology stimulates weight loss and improves glucose homeostasis



Acknowledgments

